Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 73, Issue 2, 2009, Pages 214-221

  Marmur, Jonathan D ^a   Poludasu, Shyam ^a   Lazar, Jason ^a   Cavusoglu, Erdal ^a  

^a SUNY Downstate Medical Center   (United States)

Author keywords

Bolus only; Glycoprotein; IIb IIIa inhibitors; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TIROFIBAN;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAL IMPLANTATION; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ARTERY DISEASE; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STENTS; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 60749105725     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21773     Document Type: Article

References (25)

1. Marmur JD, Mitre CA, Barnathan E, Cavusoglu E. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the EPIC trial. Am Heart J 2006;152:876-881.
2. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol 2006;18:521-526.
3. Fischell TA, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: A safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol 2006;18:487-491.
4. Bertrand OF, De Larochellière R, Rodés-Cabau J, Proulx G, Gleeton O, Nguyen CM, Déry JP, Barbeau G, Noël B, Larose E, Poirier P, Roy L; Early Discharge After Transradial Stenting of Coronary Arteries Study Investigators. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114: 2636-2643.
5. Marmur JD, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E. High-dose tirofiban administered as bolusonly during percutaneous coronary intervention. J Invasive Cardiol 2008;20:53-58.
6. Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. Ascertainment of vital status through the national death index and the social security administration. Am J Epidemiol 1985;121:754-766.
7. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article: A report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002;106:1893-1900.
8. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115: 256-265.
9. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention:REPLACE-2 randomized trial. JAMA 2003;289: 853-863.
10. Groeneveld PW, Matta MA, Greenhut AP, Yang F. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 2008;51:2017-2024.
11. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
12. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol 2001;87:537-541.
13. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O 'Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008;51:529-535.
14. Feit F. Bivalirudin: Bleeding analysis of REPLACE-2 [TCTMD Webcast series]. New York: NY: Cardiovascular Research Foundation. Presented at: ACUITY Webcast Series; April 26, 2004. Available at:http://tctmd.com/ descwebcasts/one.html?webcast_id=301.
15. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703.
16. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003;92:930-935.
17. Kim P, Dixon S, Eisenbrey AB, O'Malley B, Boura J, O'Neill W. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007;30(10Suppl 2):II35-II43.
18. Nikolsky E, Lincoff AM, Mehran R, Harrington RA, Bittle JA, Feit F, Dangas G, Solinas E, Pucelikova T, Kimura M, De Los Santos F, Stone GW. Implications of Hemoglobin Decrease in the Absence of Overt Bleeding After Percutaneous Coronary Intervention; ABSTRACTS - Innovation in Intervention: i2 Summit 2007, #2805-3.
19. Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. Am J Cardiol 2005; 96:474-481.
20. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000;139 (2 Part 2):S38-S45.
21. Bertrand OF, Rodés-Cabau J, Larose E, Nguyen CM, Roy L, Déry JP, Courtis J, Nault I, Poirier P, Costerousse O, De Larochellière R. One-year clinical outcome after abciximab bolusonly compared with abciximab bolus and 12-hour infusion in the randomized early discharge after transradial stenting of coronary arteries (EASY) study. Am Heart J 2008;156:135-140.
22. Kini AS, Chen VHT, Krishnan P, Lee P, Kim MC, Mares A, Suleman J, Moreno PR, Sharma SK. Bolus-only versus bolus + infusion of glycoprotein IIb/ IIIa inhibitors during percutaneous coronary intervention. Am Heart J (in press). Corrected Proof, Available online 2 July 2008.
23. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization, Am J Med 2002;113:1-6.
24. Gottlieb SS. Dead is dead-artificial definitions are no substitute. Lancet 1997;349:662-663.
25. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: Time for a reassessment? J Am Coll Cardiol 1999;34:618-620.